University of Queensland researchers who mapped cancer cell "neighborhoods" in the most common type of lung cancer have found ...
Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...
Comprehensive biomarker testing is crucial for NSCLC treatment, yet disparities exist between academic and community settings ...
SurvivorNet on MSN
Could timing give your cancer treatment a boost? New study on the best time to receive immunotherapy & chemo for non-small cell lung cancer
A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...
A 55 year-old struck with 'incurable' stage 4 lung cancer six years ago that spread to his brain has miraculously seen the ...
NCCN's newly updated NSCLC guidelines add sevabertinib as a treatment option and datopotamab deruxtecan-dlink a potential preferred option.
Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease ...
The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.
On January 12, NP-G2-044 (Prilukae), a novel oral fascin inhibitor earned ODD for the treatment of pancreatic cancer. This designation covers the use of the agent as monotherapy and in combination ...
Summit Therapeutics (SMMT) stock jumps as the FDA accepts its marketing application for lead asset ivonescimab, a rival to ...
In this phase 2 study, researchers explored whether fecal microbiota transplant could overcome resistance to immune checkpoint inhibition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results